UK's Cell Medica closes £17 million round
This article was originally published in Scrip
Executive Summary
Cell Medica, a UK firm developing immune cell-based therapies, has closed a £17 million funding round which includes a significant contribution from a Texan state fund for cancer research. The firm is to begin new operations in Texas focused on cancer immunotherapy as a result of the funding, which will also finance ongoing immune reconstitution studies in Europe.